[Long-term treatment with psychoverlan in children and adolescents with behavior disorders].
Numerous pharmacological and clinical long-term studies on mono-magnesium-L-glutamate-hydrobromide. H2O were reason to undertake another trial in adolescents with reactive behavioral abnormalities. The aim of the study was to assess the effecacy of Psychoverlan in abolishing or improving these symptoms and to reveal any possible drug-induced side effects. In a long-term study 19 young females were treated with Psychoverlan capsules or syrup for an average of 11.4 months. Intolerance phenomena and side-effects were not seen. It was even decided to increase the standard dose. None of the patients developed brominism or bromine intoxication. The general state of health of 13 of the 19 subjects was improved by the harmonizing effect of the drug on psychic and vegetative functions. Tiredness and somnolence were not observed.
D000293:Adolescent; D001289:Attention Deficit Disorder with Hyperactivity / Q000188:drug therapy*; D001966:Bromine / Q000627:therapeutic use*; D002648:Child; D004341:Drug Evaluation; D005260:Female; D005971:Glutamates / Q000627:therapeutic use*; D006801:Humans; D008274:Magnesium / Q000627:therapeutic use*; D008297:Male; D011618:Psychotic Disorders / Q000188:drug therapy*; D014149:Tranquilizing Agents / Q000627:therapeutic use*
D005971:Glutamates; D014149:Tranquilizing Agents; D008274:Magnesium; D001966:Bromine
Langzeitbehandlung verhaltensauffälliger Kinder und Jugendlicher mit Psychoverlan.